Preclinical antitumor activity of an anti-HER2/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor

被引：0
|
作者：
Zhong, Helen
Xiong, Yan
Huang, Han
Pan, Yuming
Cao, Lijin
Liu, Shen
Wang, Na
Sun, Bing
Liu, Dingguo
Yuan, Wei
Fang, Jan
Bao, Haifeng
机构：
[1] BiOneCure Therapeut, Germantown, MD USA
[2] BiOneCure Therapeut LLC, Germantown, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15013
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A novel bispecific antibody-drug conjugate targeting HER2 and Trop-2 displays potent antitumor activity in a variety of tumor models with promising preclinical characteristics
    Zhong, Haihong
    Xiong, Yan
    Huang, Han
    Pan, Yuming
    Wang, Na
    Sun, Bin
    Liu, Shen
    Yuan, Wei
    Liu, Dingguo
    Fang, Jan
    Bao, Haifeng
    CANCER RESEARCH, 2024, 84 (06)
  • [2] YH012, a novel bispecific anti-HER2 and TROP2 antibody-drug conjugate, exhibits potent antitumor efficacy
    Shang, Chengzhang
    Yang, Liu
    Zhang, Jiyong
    Han, Yanfei
    Li, Zhuolin
    Han, Zhenyan
    Li, Jun
    Meng, Ying
    An, Gao
    Yang, Hao
    An, Wenqian
    Chen, Lei
    Charpentier, John
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Preclinical studies of an anti-HER2 antibody-drug conjugate.
    Koeppen, H
    Dugger, D
    Tibbitts, J
    Leipold, D
    Reynolds, T
    Leach, W
    Slikowski, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8980S - 8980S
  • [4] DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
    Okajima, Daisuke
    Yamaguchi, Junko
    Kitamura, Michiko
    Kamei, Reiko
    Maejima, Takanori
    Shibutani, Tomoko
    Yasuda, Satoru
    Toki, Tadashi
    Karibe, Tsuyoshi
    Fujitani, Tomomichi
    Nakada, Takashi
    Goto, Riki
    Noguchi, Yutaka
    Abe, Yuki
    Agatsuma, Toshinori
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [5] Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd.
    Okajima, Daisuke
    Yasuda, Satoru
    Yokouchi, Yusuke
    Fujitani, Tomomichi
    Sakurai, Ken
    Yamaguchi, Junko
    Kitamura, Michiko
    Terauchi, Tomoko
    Shibutani, Tomoko
    Aida, Tetsuo
    Nakada, Takashi
    Tokuhiro, Shinya
    Toki, Tadashi
    Noguchi, Yutaka
    Abe, Yuki
    Agatsuma, Toshinori
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Development of a potent Trop-2 antibody-drug conjugate, BAT8003, for the treatment of Trop-2 positive gastric tumors
    Tang, Weijia
    Mei, Xingxing
    Ou, Ziqiang
    Gan, Jirong
    Li, Shengfeng
    Yu, Jin-Chen
    CANCER RESEARCH, 2019, 79 (13)
  • [7] A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2-or EGFR-targeted ADCs
    Huang, Huoying
    Zhou, Yuxin
    Shang, Chengzhang
    Zhang, Yifu
    Shen, Yuelei
    INVESTIGATIONAL NEW DRUGS, 2025,
  • [8] A Patient With Metastatic Uterine Carcinosarcoma With Presumed Pneumonitis Secondary to Investigational Drug Db-1303, an Antibody-Drug Conjugate Comprised of Anti-HER2 Monoclonal Antibody Linked to a DNA Topoisomerase I Inhibitor
    Dwyer, C.
    Song, D.
    Geyer, A. I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [9] Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker
    Liubomirski, Yulia
    Tiram, Galia
    Scomparin, Anna
    Gnaim, Samer
    Das, Sayantan
    Gholap, Sachin
    Ge, Liang
    Yeini, Eilam
    Shelef, Omri
    Zauberman, Arie
    Berger, Nir
    Kalimi, Doron
    Toister-Achituv, Mira
    Schroeter, Christian
    Dickgiesser, Stephan
    Tonillo, Jason
    Shan, Min
    Deutsch, Carl
    Sweeney-Lasch, Stanley
    Shabat, Doron
    Satchi-Fainaro, Ronit
    JOURNAL OF CONTROLLED RELEASE, 2024, 367 : 148 - 157
  • [10] Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker
    Liubomirski, Yulia
    Tiram, Galia
    Scomparin, Anna
    Gnaim, Samer
    Das, Sayantan
    Gholap, Sachin
    Ge, Liang
    Yeini, Eilam
    Shelef, Omri
    Zauberman, Arie
    Berger, Nir
    Kalimi, Doron
    Toister-Achituv, Mira
    Schroter, Christian
    Dickgiesser, Stephan
    Tonillo, Jason
    Shan, Min
    Deutsch, Carl
    Sweeney-Lasch, Stanley
    Shabat, Doron
    Satchi-Fainaro, Ronit
    CANCER RESEARCH, 2024, 84 (06)
12345